Chemotargets

Chemotargets is a Barcelona-based drug discovery company that leverages its proprietary CLARITY AI platform to accelerate the development of new medicines. Founded in 2006 as a spin-off from the IMIM Hospital del Mar Medical Research Institute, the company provides advanced computational solutions for predicting the safety and efficacy of small molecules. The CLARITY platform is notably used by the U.S. FDA's Center for Drug Evaluation and Research to assist in the evaluation of drug safety. Chemotargets operates through a dual business model, offering software licensing and consulting services to global pharmaceutical companies while also advancing its own internal pipeline. Their internal research focuses primarily on oncology and central nervous system disorders, utilizing AI to identify novel targets and optimize lead compounds. In 2020, the company underwent a significant transformation following a majority investment by Genesis Ventures and the Prous Institute for Biomedical Research.